Consensus recommendations for ASCVD risk reduction in hypertriglyceridemia

The ACC has published an Expert Consensus Decision Pathway (ECDP) on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia. The ECDP provides practical guidance in the form of clinical workflows on the management of hypertriglyceridemia in 4 patient populations:

• Adults with clinical ASCVD and fasting triglycerides (TG) ≥150 or nonfasting TG ≥175 mg/dL and TG <500 mg/dL.
• Adults aged ≥40 years with Diabetes Mellitus, no ASCVD, and fasting TG ≥150 mg/dL or nonfasting TG ≥175 mg/dL and TG <500 mg/dL.
• Adults aged ≥20 Years with no ASCVD or Diabetes Mellitus, and fasting triglycerides ≥150 mg/dL or nonfasting TG ≥175 mg/dL and TG <500 mg/dL.
• Adults aged ≥20 years with severe hypertriglyceridemia, TG ≥500 mg/dL, and especially TG ≥1000 mg/dL.

The ECDP provides information about secondary causes of hypertriglyceridemia, lifestyle modifications in patients with hypertriglyceridemia (including detailed nutrition recommendations for patients with mild, moderate or severe hypertriglyceridemia), and use of statins and TG risk-based non-statin therapies for ASCVD risk reduction.

Find the 2021 ACC Expert Consensus Decision Pathway online at J Am Coll Cardiol.